{"product_id":"aytubio-business-model-canvas","title":"Aytu Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the strategic playbook: concise Business Model Canvas for investors and founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Aytu's strategic playbook with our concise Business Model Canvas—see how its value propositions, channels, partnerships and revenue streams interlock to drive growth. Ideal for investors, founders, and analysts seeking actionable insights. Purchase the full editable Canvas in Word\/Excel to apply and benchmark instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma manufacturers \u0026amp; licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with originators to in-license novel primary care and pediatric therapies for commercialization, securing product rights, tech transfer, and ongoing manufacturing support. Deals typically include milestones and royalties, commonly ranging from low single-digit to mid-teens percent. This model supplies a steady flow of differentiated products while avoiding the high fixed costs of discovery and early R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUse GMP-certified CMOs to produce finished dosage forms at scale; the global pharma CMO market was estimated at $82B in 2024, evidencing capacity advantages. CMOs deliver quality, supply continuity and 10–25% lower COGS versus in-house runs, enabling rapid launches and lifecycle changes. Multi-sourcing across 2–3 CMOs reduces single‑source risk and preserves commercial continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers \u0026amp; PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnering with national wholesalers (McKesson, Cardinal, AmerisourceBergen cover ~85% of U.S. drug distribution), specialty distributors and PBMs expands Aytu’s availability and access. PBM relationships, which manage roughly 80% of prescription lives, drive formulary placement and rebate structures. Efficient distribution improves service levels and reduces stockouts, supporting reach into retail and specialty pharmacies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical research \u0026amp; regulatory consultants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngage CROs and regulatory advisors to run studies, manage submissions, and maintain compliance, leveraging external teams to accelerate time-to-approval and label updates. External expertise optimizes trial design and evidence packages, shortening development timelines by up to 25% (2024 CRO benchmarks) and improving approval success rates. Outsourcing reduces internal fixed costs while preserving regulatory rigor and can lower development spend by ~20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse CROs for end-to-end study execution\u003c\/li\u003e\n\u003cli\u003eRegulatory advisors for submissions and label strategy\u003c\/li\u003e\n\u003cli\u003e25% faster time-to-approval (2024)\u003c\/li\u003e\n\u003cli\u003e~20% cost reduction vs fully in-house\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-merger integration with Alimera Sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-merger integration with Alimera Sciences (completed January 2024) leverages Alimera’s ophthalmology infrastructure and shared services to consolidate procurement, finance and quality systems, driving economies of scale. Cross-selling and portfolio rationalization sharpen commercial focus, while unified governance aligns pipeline priorities and commercial execution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMerger date: January 2024\u003c\/li\u003e\n\u003cli\u003eShared services: procurement, finance, quality\u003c\/li\u003e\n\u003cli\u003eBenefits: economies of scale, cross-selling, portfolio focus\u003c\/li\u003e\n\u003cli\u003eGovernance: aligned pipelines and commercial priorities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner to in-license pediatric assets: \u003cstrong\u003e10-25%\u003c\/strong\u003e lower COGS via GMP CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with originators to in-license pediatric\/primary care assets (royalties low-single to mid-teens) and use GMP CMOs (global CMO market $82B in 2024) for 10–25% lower COGS. National wholesalers (~85% U.S. reach) and PBMs (~80% lives) expand access. Alimera merger Jan 2024 creates shared services and cross-sell scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO market\u003c\/td\u003e\n\u003ctd\u003e$82B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler reach\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM lives\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Aytu that maps all nine BMC blocks—customer segments, value propositions, channels, revenue and cost streams, key partners, activities, resources, and customer relationships—into a single investor-ready narrative. Includes competitive advantages, SWOT-linked insights, and operational and financial implications for presentations, funding, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Aytu’s strategy into a digestible one-page snapshot that saves hours of structuring, makes core components editable for fast iteration, and is perfect for team collaboration, boardrooms, or comparing models side-by-side.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-licensing \u0026amp; portfolio management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSource, evaluate, and negotiate rights to novel or de‑risked primary care and pediatric therapies, prioritizing assets addressing clear unmet needs; primary care represents roughly 50% of U.S. outpatient visits, signaling scale. Continuously prune and optimize the portfolio, targeting payer acceptance thresholds typically above 60% to ensure commercial viability. Manage milestones, IP, exclusivity windows and milestone-driven payments to protect value and accelerate launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access \u0026amp; pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSecure payer coverage by negotiating rebates (commonly 20–50% in 2024) and targeting favorable formulary tiers to maximize access; maintain HEOR and budget-impact models demonstrating value at $50–150k per QALY thresholds. Implement patient-assistance and copay programs to preserve adherence while monitoring rebating against gross-to-net dynamics to protect realized net revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs \u0026amp; evidence generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRun post-marketing studies, RWE and safety surveillance to boost adoption, leveraging a global RWE market that surpassed $3 billion in 2024; engage KOLs and advisory boards for real-world validation; provide compliant scientific exchange and education across HCP channels; feed insights into labeling and positioning to support uptake and reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperate field sales targeting pediatricians and primary care physicians, focusing on roughly 67,000 US pediatricians (AAP 2024); drive omnichannel HCP engagement and sampling to convert trials to prescriptions; manage supply, demand planning and trade promotions to stabilize stock and margins; optimize digital and peer-to-peer programs to expand reach and improve adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField sales: target pediatricians\/PCPs (~67,000)\u003c\/li\u003e\n\u003cli\u003eOmnichannel sampling: HCP engagement\u003c\/li\u003e\n\u003cli\u003eSupply \u0026amp; demand: planning \u0026amp; trade promotions\u003c\/li\u003e\n\u003cli\u003eDigital\/peer-to-peer: boost reach \u0026amp; adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory, quality \u0026amp; PV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintain cGMP and robust pharmacovigilance with 15-day expedited reporting for serious unexpected adverse reactions and periodic safety reports (PSURs every 6 months for new products, then annually) while executing CMC updates and lifecycle management through timely regulatory variations. Ensure labeling compliance across markets (EU requires materials in 24 official languages) and proactively manage inspections, audits, 483 responses, and change controls with documented SOPs and CAPAs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecGMP compliance\u003c\/li\u003e\n\u003cli\u003e15-day expedited PV reporting\u003c\/li\u003e\n\u003cli\u003ePSUR: 6-month then annual\u003c\/li\u003e\n\u003cli\u003eCMC change submissions\u003c\/li\u003e\n\u003cli\u003eLabeling: 24 EU languages\u003c\/li\u003e\n\u003cli\u003eInspections, 483s, CAPA-driven change control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSource pediatric primary-care assets; secure payer coverage, RWE-driven adoption, EU labeling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSource and optimize primary care\/pediatric assets addressing unmet needs (primary care ~50% of US outpatient visits); negotiate rights, milestones, and payer-ready dossiers. Secure coverage via rebates (20–50% in 2024), HEOR ($50–150k\/QALY) and patient-access programs while managing gross-to-net. Drive adoption with RWE (\u0026gt; $3B market 2024), field sales to ~67,000 pediatricians, cGMP\/PV (15-day expedited, PSUR 6m→annual) and labeling across 24 EU languages.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\/data (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortfolio sourcing\u003c\/td\u003e\n\u003ctd\u003ePrimary care ~50% US visits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer strategy\u003c\/td\u003e\n\u003ctd\u003eRebates 20–50%; $50–150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE \u0026amp; adoption\u003c\/td\u003e\n\u003ctd\u003eRWE market \u0026gt;$3B; 67,000 pediatricians\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/PV\u003c\/td\u003e\n\u003ctd\u003e15-day PV; PSUR 6m→annual; EU 24 langs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Aytu Business Model Canvas you’ll receive—this is not a mockup or sample. Upon purchase you’ll instantly get the same complete, fully editable file formatted for practical use and presentation. No hidden pages or altered content—what you see here is exactly what you’ll download and apply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct portfolio \u0026amp; IP licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeld rights and licenses for marketed prescription products in primary care and pediatrics underpin Aytu’s asset base, enabling commercialization across outpatient channels. Contractual exclusivity windows and registered trademarks protect product value and limit direct competition. Precise labeling and approved indications define addressable markets and reimbursement pathways, while milestone and royalty obligations materially shape product-level economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial team \u0026amp; HCP relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSales, market access, and medical teams maintain established physician networks to drive targeted detailing and specialty uptake. Therapeutic expertise across teams enables focused messaging that improves prescriber conversion. Access teams lead payer negotiations to secure coverage and optimize reimbursement. Strong HCP relationships underpin formulary wins and sustained prescriber adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory approvals \u0026amp; quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExisting NDAs, ANDAs and supplements underpin Aytu’s commercialization by providing market entry pathways and exclusivity leverage. Robust QMS and pharmacovigilance systems ensure ongoing regulatory compliance and patient safety. Comprehensive documentation and audit readiness reduce inspection-related risk and downtime. These resources facilitate rapid regulatory changes and timely submissions to regulators.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData assets \u0026amp; analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eData assets including claims, prescription, and CRM records drive precise targeting and demand forecasting; in 2024 these linked datasets shortened campaign lead times and improved forecast accuracy for peers in specialty pharma. HEOR datasets underpin payer access arguments, safety databases enable near real-time signal detection, and analytics continuously optimize promotion and inventory.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClaims\/prescription\/CRM: targeted outreach, better forecasting\u003c\/li\u003e\n\u003cli\u003eHEOR: payer access support\u003c\/li\u003e\n\u003cli\u003eSafety DBs: signal detection\u003c\/li\u003e\n\u003cli\u003eAnalytics: promotion and inventory optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-merger shared infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-merger shared infrastructure grants access to Alimera’s corporate functions, procurement, and finance, centralizing decision-making and compliance. Combined IT, ERP, and trade networks streamline order-to-cash and reduce duplication, improving operational efficiency. A larger procurement scale strengthens negotiating leverage to lower COGS while an integration roadmap preserves business continuity during migration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to Alimera corporate functions\u003c\/li\u003e\n\u003cli\u003eUnified IT\/ERP\/trade networks\u003c\/li\u003e\n\u003cli\u003eScale-driven COGS reduction\u003c\/li\u003e\n\u003cli\u003eIntegration roadmap ensures continuity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActive licenses, integrated data and commercial teams enable scalable outpatient access in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeld prescription rights, trademarks, and approved indications enable outpatient commercialization and reimbursement access. Established sales, market access, and medical teams sustain HCP networks and formulary traction. Linked claims\/prescription\/CRM and safety\/HEOR datasets plus Alimera corporate access support forecasting, access negotiations, and scaled operations in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 Status\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRights \u0026amp; licenses\u003c\/td\u003e\n\u003ctd\u003eActive\u003c\/td\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\/Medical teams\u003c\/td\u003e\n\u003ctd\u003eOperational\u003c\/td\u003e\n\u003ctd\u003ePrescriber uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData assets\u003c\/td\u003e\n\u003ctd\u003eLinked\u003c\/td\u003e\n\u003ctd\u003eTargeting\/forecasting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlimera integration\u003c\/td\u003e\n\u003ctd\u003eAccessible\u003c\/td\u003e\n\u003ctd\u003eScale\/efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically differentiated therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinically differentiated therapies offer novel or improved treatments addressing unmet needs in primary care and pediatrics, where children comprise about 22% of the US population. Focus on superior efficacy, safety, and ease of use drives prescriber adoption. Real-world evidence aligned with the FDA RWE framework (2018) demonstrates meaningful outcome improvements in routine practice. Sustained clinical differentiation preserves prescriber preference and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved access \u0026amp; affordability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeliver broad payer coverage supported by rebates and assistance programs, with commercial formulary access estimated above 80% in 2024. Transparent pricing and patient support reduce barriers, and copay cards have been shown to cut prescription abandonment by up to 30%. Lower out-of-pocket costs correlate with improved persistence, often raising adherence rates by double-digit percentages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvenience \u0026amp; adherence support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProvide user-friendly formulations and clear dosing to reduce administration errors; WHO estimates adherence for chronic diseases in developed countries averages 50%. Education and automated reminders help families manage therapy and refill\/savings tools simplify continuity, addressing the $100–300 billion annual US cost attributed to medication nonadherence. Better adherence translates into measurable outcome gains and lower utilization. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable supply \u0026amp; service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReliable supply and service ensure consistent product availability via strong trade operations, targeting a 98% fill rate in 2024. Rapid response protocols deliver average 24-hour triage for shortages or backorders. Dedicated field support and medical information for HCPs strengthen trust and customer loyalty.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003efill_rate_2024: 98% target\u003c\/li\u003e\n\u003cli\u003eresponse_time: 24h average\u003c\/li\u003e\n\u003cli\u003ehcp_support: field + med info\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanded capabilities via merger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExpanded capabilities via merger unlock greater economies and geographic reach, enabling broader market access and lower unit costs through shared infrastructure and sales channels. The combined portfolio fosters cross-portfolio innovation and faster commercialization by leveraging complementary R\u0026amp;D and distribution networks. A stronger balance of commercial and development resources accelerates realization of pipeline value and shortens time-to-revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverage combined scale for cost and reach\u003c\/li\u003e\n\u003cli\u003eCross-portfolio innovation and distribution\u003c\/li\u003e\n\u003cli\u003eBalanced commercial and development resources\u003c\/li\u003e\n\u003cli\u003eFaster pipeline value realization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric therapies: prescriber preference, \u003cstrong\u003e22%\u003c\/strong\u003e reach, \u003cstrong\u003e\u0026gt;80%\u003c\/strong\u003e formulary, \u003cstrong\u003e24h\u003c\/strong\u003e response\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinically differentiated therapies targeting pediatrics (22% of US pop) drive prescriber preference via superior efficacy, safety and RWE. Broad payer access (\u0026gt;80% formulary 2024), rebates and copay support cut abandonment ~30% and raise adherence vs ~50% baseline. Reliable supply (98% fill rate target) and 24h response preserve continuity and accelerate uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric population\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate\u003c\/td\u003e\n\u003ctd\u003e98% target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResponse time\u003c\/td\u003e\n\u003ctd\u003e24h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbandonment reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated HCP engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated HCP engagement delivers personalized detailing to pediatricians and PCPs with samples, clinical data, and on-demand support; omnichannel touchpoints (in-person, tele-detailing, email) maintain monthly frequency and consistency. 2024 industry data show 68% of physicians favor integrated digital\/in-person outreach and samples can boost prescribing rates by ~40%, while continuous feedback capture refines messaging and improves HCP satisfaction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer partnership management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing dialogue with payers and PBMs—which control roughly 80% of US prescriptions—secures and restores access while sharing robust outcomes and economic data to demonstrate value. Contracts include negotiated pricing and performance guarantees tied to predefined clinical\/economic metrics. Proactive formulary-change management and rapid real-world evidence updates mitigate delisting risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatient support programs deliver onboarding, copay assistance and reimbursement navigation, plus adherence tools and education; 2024 industry data show such programs can boost treatment initiation by up to 30% and improve persistence roughly 20%, while centralized patient hubs streamline prior authorizations—cutting turnaround time and abandonment rates significantly and improving net prescription fill rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL networks \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKOL networks and education leverage advisory boards and speaker programs to disseminate evidence, support compliant CME and scientific exchange, and drive advocacy and guideline influence, enhancing credibility and uptake; in 2024 the global CME market was estimated at $6.2B, underscoring scale and reach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvisory boards: strategic evidence dissemination\u003c\/li\u003e\n\u003cli\u003eSpeaker programs: scalable education\u003c\/li\u003e\n\u003cli\u003eCME support: compliant scientific exchange\u003c\/li\u003e\n\u003cli\u003eGuideline influence: increases adoption and credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade \u0026amp; pharmacy collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWork with wholesalers and retail and specialty pharmacies to secure stocking and white‑glove service, sharing demand forecasts and inventory plans to reduce stockouts and accelerate patient starts. Implement targeted pharmacy education programs to improve clinical understanding and adherence support, driving higher fill rates and faster time to therapy. Collaborations focus on measurable KPIs and contractual SLAs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner scope: wholesalers, specialty, retail pharmacies\u003c\/li\u003e\n\u003cli\u003eData sharing: demand forecasts, inventory plans\u003c\/li\u003e\n\u003cli\u003ePrograms: pharmacy education, adherence support\u003c\/li\u003e\n\u003cli\u003eOutcomes: higher fill rates, faster time to therapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel HCP engagement \u003cstrong\u003e+40%\u003c\/strong\u003e; PSPs +30% starts; payers ~80% control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated omnichannel HCP engagement (68% prefer integrated outreach) with samples (+~40% prescribing) and monthly touchpoints; payer\/PBM relations (control ~80% US scripts) with performance contracts protect access. Patient support programs raise starts ~30% and persistence ~20%, while KOL\/CME ($6.2B 2024) and pharmacy partnerships lift fill rates and reduce PA turnaround.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician preference\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample impact on scripts\u003c\/td\u003e\n\u003ctd\u003e+40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer control of scripts\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient start uplift\u003c\/td\u003e\n\u003ctd\u003e+30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersistence uplift\u003c\/td\u003e\n\u003ctd\u003e+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCME market\u003c\/td\u003e\n\u003ctd\u003e$6.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField sales \u0026amp; MSL outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect in-person engagements with HCPs and institutions target a US physician base of ~1,062,205 (AAMC 2023) to influence prescribing behavior. Tailored messaging by specialty and territory increases relevance; MSLs deliver deeper scientific dialogue to KOLs and clinicians. Field efforts support uptake within a market that filled ~6.44B prescriptions in 2023 (IQVIA), driving prescriptions and clinician confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital HCP platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital HCP platforms—email, webinars, e-detailing and on-demand portals—deliver targeted content that improves rep efficiency and complements field efforts; IQVIA 2024 reports digital and remote engagements now represent over 50% of HCP interactions. Engagement analytics track opens, view time and conversion to inform ROI and resource allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale \u0026amp; specialty distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational wholesalers, led by the three large distributors McKesson, AmerisourceBergen and Cardinal Health, move product to pharmacies and specialty sites. This network ensures broad U.S. geographic coverage and rapid replenishment. Contract terms and SLAs govern inventory, billing and service levels. Specialty distributors also support buy-and-bill workflows where applicable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRetail and specialty pharmacies (≈21,000 retail pharmacies in the US, 2024) dispense medicines and provide counseling; specialty channels manage complex therapies and hub services. Pharmacy programs raise adherence by up to 15% and reduce hospitalization risk, while data sharing with pharmacies can improve demand-forecast accuracy by up to 20%, enhancing supply planning and patient experience.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003edispense \u0026amp; counsel\u003c\/li\u003e\n\u003cli\u003eadherence programs +≈15%\u003c\/li\u003e\n\u003cli\u003edata shares → +≈20% forecast accuracy\u003c\/li\u003e\n\u003cli\u003eimproves patient experience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer \u0026amp; formulary pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFormulary listings, prior authorization criteria and step edits determine patient access and directly shape pull-through for Aytu products; contracted payer pathways reduce administrative friction and denials. Benefit verification and electronic prior authorization tools accelerate approvals and improve time-to-treatment. Tight payer alignment increases net realized revenue per script.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary placement impacts utilization\u003c\/li\u003e\n\u003cli\u003ePrior auth and step edits limit access\u003c\/li\u003e\n\u003cli\u003eContracts cut friction and denials\u003c\/li\u003e\n\u003cli\u003eBenefit-verification speeds approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultichannel: \u003cstrong\u003e1,062,205\u003c\/strong\u003e MDs + \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e digital drive uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMultichannel outreach combines ~1,062,205 US physicians (AAMC 2023) via field reps\/MSLs and digital (\u0026gt;50% HCP interactions, IQVIA 2024) to drive uptake across a 6.44B‑script market (IQVIA 2023). Distribution via McKesson\/AmerisourceBergen\/Cardinal Health plus specialty distributors ensures national reach and buy‑and‑bill support. Pharmacy and payer channels (≈21,000 retail pharmacies, 2024) elevate adherence (~+15%) and forecast accuracy (~+20%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP field\/digital\u003c\/td\u003e\n\u003ctd\u003e1,062,205 physicians; \u0026gt;50% digital\u003c\/td\u003e\n\u003ctd\u003ePrescribing influence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eTop3 wholesalers\u003c\/td\u003e\n\u003ctd\u003eNational coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e≈21,000 retail\u003c\/td\u003e\n\u003ctd\u003e+15% adherence; +20% forecast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatricians \u0026amp; family medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediatricians and family medicine clinicians are core prescribers for pediatric indications; AAP lists ~67,000 pediatricians and AAFP reports ~92,000 family physicians in 2024. They prioritize ease-of-use and strong safety profiles, seek clear clinical guidance and rapid access to e-prescribing or samples. Their prescribing patterns drive recurring monthly prescription volume and adherence metrics critical to revenue retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary care physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary care physicians, roughly 210,000 in the US in 2024 (AMA), are high-volume prescribers for common conditions and drive baseline demand. They prioritize clear efficacy and patient convenience, favoring short, evidence-backed messaging. Decisions hinge on concise clinical data and payer coverage status. Engaging PCPs is essential for broad market penetration and rapid uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTarget payers and PBMs across commercial (~180M covered lives), Medicaid (~82M enrollees in 2024), and Medicare Part D (~51M enrollees) demand clear HEOR demonstrating cost-effectiveness and QALY gains to justify placement. Negotiate value-based contracting, rebates, and utilization edits with the three major PBMs that control ~80% of claims. Contract terms must limit patient cost share and prior authorization to optimize adherence and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients \u0026amp; caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and caregivers—children, adolescents, and families—require affordable, simple therapies with accessible support. WHO reports adherence to long-term therapies averages ~50%; education interventions commonly increase adherence by ~20–30% (2024). Word-of-mouth from caregivers significantly amplifies uptake and brand trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: pediatric patients \u0026amp; families\u003c\/li\u003e\n\u003cli\u003eNeeds: affordability, simplicity, support\u003c\/li\u003e\n\u003cli\u003eFact: ~50% average adherence (WHO)\u003c\/li\u003e\n\u003cli\u003eImpact: education +20–30% adherence\u003c\/li\u003e\n\u003cli\u003eGrowth: caregiver word-of-mouth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals \u0026amp; clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and clinics—including institutional buyers and an estimated 6,000 US hospitals plus over 200,000 outpatient clinics in 2024—demand supply reliability and compliant contracting to meet procurement and regulatory standards. They materially influence therapy initiation and protocols via formulary committees and ED\/infusion center practices, and serve as localized volume anchors for rollouts and account-based pricing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstitutional buyers: large contracts, GPO influence\u003c\/li\u003e\n\u003cli\u003eOutpatient clinics: high touch, recurring demand\u003c\/li\u003e\n\u003cli\u003eSupply reliability: critical for clinical adoption\u003c\/li\u003e\n\u003cli\u003eLocalized volume anchors: enable regional scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric, PCP \u0026amp; payer roles shape access for \u003cstrong\u003e~313M\u003c\/strong\u003e lives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePediatricians (~67,000) and family physicians (~92,000) drive pediatric prescriptions; PCPs (~210,000) provide baseline volume. Payers\/PBMs (commercial ~180M lives, Medicaid ~82M, Medicare D ~51M) require HEOR and favorable coverage. Patients\/caregivers need affordability and support to improve ~50% adherence (+20–30% with education).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eCount\/Coverage (2024)\u003c\/th\u003e\n\u003cth\u003eKey Need\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatricians\/FPs\u003c\/td\u003e\n\u003ctd\u003e~159,000\u003c\/td\u003e\n\u003ctd\u003eSafety, e-prescribe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCPs\u003c\/td\u003e\n\u003ctd\u003e~210,000\u003c\/td\u003e\n\u003ctd\u003eEvidence, convenience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e~313M lives\u003c\/td\u003e\n\u003ctd\u003eHEOR, value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003eAdherence ~50%\u003c\/td\u003e\n\u003ctd\u003eAffordability, support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Clinics\u003c\/td\u003e\n\u003ctd\u003e~6,000\/200,000\u003c\/td\u003e\n\u003ctd\u003eSupply, contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of goods sold (COGS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAytu's COGS centers on CMO-led manufacturing, packaging and quality control, tapping a global contract manufacturing market valued at roughly 130 billion USD in 2024 to source capacity efficiently. Freight and distribution fees—including cold chain where applicable—are material line items that can vary 5–12% of COGS depending on channel. Serialization and regulatory compliance drove incremental costs in 2024, often adding several percent per unit for labeling and track-and-trace. Scale, long-term procurement and batch consolidation can reduce unit costs materially, commonly in the mid-teens percent range as volumes grow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial \u0026amp; promotion spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial \u0026amp; promotion spend funds a targeted sales force, digital marketing, sampling and educational programs, plus congresses and speaker bureaus, backed by CRM and analytics tools to drive ROI-driven allocation across brands; in 2024 digital promotion accounted for over 50% of pharma promotional budgets, shifting spend toward measurable, data-driven channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access \u0026amp; rebates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRebates, chargebacks and admin fees paid to payers and PBMs constitute a major line-item, alongside copay assistance and patient programs that drive uptake but increase deductions. In 2024 pharmaceutical gross-to-net deductions averaged roughly 30–40% of list price, materially reducing reported revenue. Aytu manages this exposure through disciplined contracting, formulary strategies and targeted patient-program budgeting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eR\u0026amp;D and medical affairs for Aytu cover clinical studies and RWE generation (late‑stage trials often exceed $20M per study), medical information, regulatory submissions\/label expansions, and continuous safety surveillance with pharmacovigilance systems; many small biotechs outsource portions, keeping fixed costs moderate while variable trial costs drive spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical studies: late‑stage \u0026gt;$20M\u003c\/li\u003e\n\u003cli\u003eRWE \u0026amp; med info: ongoing operational spend\u003c\/li\u003e\n\u003cli\u003eRegulatory: submissions\/label expansions\u003c\/li\u003e\n\u003cli\u003eSafety\/PV: continuous surveillance\u003c\/li\u003e\n\u003cli\u003eOutsourcing: moderates fixed cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and post-merger integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpg covers corporate functions legal finance includes facilities and audit expenses while post-merger integration focuses on systems consolidation one-time costs after the alimera merger with targeted synergies to reduce run-rate.\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate functions: IT, legal, finance\u003c\/li\u003e\n\u003cli\u003eIntegration: systems consolidation, one-time costs\u003c\/li\u003e\n\u003cli\u003eFacilities and audit expenses\u003c\/li\u003e\n\u003cli\u003eObjective: run-rate synergies post-merger\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pg\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost drivers: CMO market \u003cstrong\u003e$130B\u003c\/strong\u003e, freight \u003cstrong\u003e5–12%\u003c\/strong\u003e, GTN \u003cstrong\u003e30–40%\u003c\/strong\u003e, digital \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e, R\u0026amp;D \u003cstrong\u003e\u0026gt;$20M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAytu's cost structure is driven by CMO manufacturing (global market ~$130B in 2024), freight\/distribution (5–12% of COGS), serialization\/regulatory add-ons, and scale-driven unit cost declines. Commercial spend favors digital (\u0026gt;50% of promo budgets in 2024). Gross-to-net deductions averaged 30–40%, while late-stage R\u0026amp;D programs often exceed $20M per study.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine item\u003c\/th\u003e\n\u003cth\u003e2024 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS \/ CMO\u003c\/td\u003e\n\u003ctd\u003eMarket ~$130B; key cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight \u0026amp; distribution\u003c\/td\u003e\n\u003ctd\u003e5–12% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross-to-net\u003c\/td\u003e\n\u003ctd\u003e30–40% of list\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital promo\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% of promo spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$20M per study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales to wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet sales from shipments to authorized distributors and wholesalers constitute Aytu’s primary top-line channel, recognized net of returns and chargebacks under revenue accounting.\u003c\/p\u003e\n\u003cp\u003eThese sales drive core revenue and are tightly linked to inventory dynamics, with channel fill rates, aged inventory and chargeback accruals materially affecting recognized net sales.\u003c\/p\u003e\n\u003cp\u003eManagement monitors distributor sell-through and return reserves to align shipments with demand and preserve gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales through specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenues derive from therapies requiring cold chain, limited distribution or clinical support; as of 2024 specialty drugs account for over 50% of U.S. drug spending while comprising roughly 2–3% of prescriptions. Selling through specialty pharmacies enables adherence programs and rich patient-data feedback to inform outcomes and payer reporting. These channels are commonly tied to payer contracts, and the higher service levels justify the channel choice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and clinic sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect and indirect sales to hospitals and outpatient clinics, including volume-tier contracts, drive initiation and continuity of treatment and stabilize regional demand; in 2024 there are roughly 6,000 US hospitals and over 230,000 outpatient clinics, offering broad addressable channels. Volume-tier contracts secure predictable unit orders and revenue cadence. Institutional deals often account for the majority of early commercial uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing, milestones \u0026amp; royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncome from out-licensing and co-promotion deals provides Aytu with upfronts and shared commercial effort; 2024 pharma deals saw median upfronts near $5M, supporting non-dilutive funding.\u003c\/p\u003e\n\u003cp\u003eMilestone payments tied to development or sales triggers commonly range $1M–$50M in 2024 deals, while royalties in partnered markets typically run 5–15%, diversifying revenue beyond direct product sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOut-licensing: upfronts ~5M (median 2024)\u003c\/li\u003e\n\u003cli\u003eMilestones: $1M–$50M per trigger (2024 ranges)\u003c\/li\u003e\n\u003cli\u003eRoyalties: 5–15% typical (2024)\u003c\/li\u003e\n\u003cli\u003eDiversification: reduces dependence on product sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient assistance-funded pull-through\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient assistance-funded pull-through drives indirect revenue lift by improving initiation and persistence; IQVIA 2024 found hub services can cut specialty drug abandonment ~30% and raise refill persistence ~15%, translating to measurable net sales growth while programs are optimized to balance gross-to-net impacts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced abandonment: ~30% (IQVIA 2024)\u003c\/li\u003e\n\u003cli\u003eIncreased persistence\/refills: ~15% (IQVIA 2024)\u003c\/li\u003e\n\u003cli\u003eTracked as net sales uplift vs gross-to-net adjustments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor-led net sales; specialty \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e of spend; partnerships median upfront \u003cstrong\u003e$5M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet sales to distributors\/wholesalers are Aytu’s primary revenue, recognized net of returns\/chargebacks and linked to inventory dynamics and sell-through. Specialty channels account for \u0026gt;50% of US drug spend in 2024 while 2–3% of scripts, enabling adherence programs and payer contracting. Partnerships: median upfronts ~$5M (2024), milestones $1M–$50M, royalties 5–15%; hub services cut abandonment ~30% and boost persistence ~15% (IQVIA 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor sales\u003c\/td\u003e\n\u003ctd\u003ePrimary\u003c\/td\u003e\n\u003ctd\u003eVolume \u0026amp; gross-to-net sensitive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty channels\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% spend; 2–3% scripts\u003c\/td\u003e\n\u003ctd\u003eHigher services, payer contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eUpfront ~$5M; milestones $1M–$50M; royalties 5–15%\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive, diversified\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHub programs\u003c\/td\u003e\n\u003ctd\u003e-30% abandonment; +15% persistence\u003c\/td\u003e\n\u003ctd\u003eNet sales uplift vs GN adjustments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097891606876,"sku":"aytubio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/aytubio-business-model-canvas.png?v=1781789054","url":"https:\/\/pestel-analysis.com\/products\/aytubio-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}